Your browser doesn't support javascript.
loading
Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1-mutant.
Alexandrescu, Sanda; Meredith, David M; Lidov, Hart G; Alaggio, Rita; Novello, Mariangela; Ligon, Keith L; Vargas, Sara O.
Afiliação
  • Alexandrescu S; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
  • Meredith DM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lidov HG; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
  • Alaggio R; Department of Pathology, Bambino Gesu Hospital, Rome, Italy.
  • Novello M; Department of Pathology, San Bartolo Hospital, Vicenza, Italy.
  • Ligon KL; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Vargas SO; Department of Pathology, Boston Children's Hospital, Boston, MA, USA.
Histopathology ; 78(2): 265-275, 2021 Jan.
Article em En | MEDLINE | ID: mdl-32692439
AIMS: Primary intracranial sarcoma, DICER1-mutant is a recently described central nervous system tumour with specific genomic and DNA-methylation profiles. Although some of its histological features (focal spindle-cell morphology, intracytoplasmic eosinophilic granules, and focal heterologous differentiation) are common across most reported cases, the presence of significant histological variability and the lack of differentiation pose diagnostic challenges. We aim to further define the immunoprofile of this tumor. METHODS AND RESULTS: We reviewed the clinical history and performed immunohistochemistry for glial fibrillary acidic protein, oligodendrocyte transcription factor 2, SOX2, SOX10, S100, histone H3 trimethylated on lysine 27 (H3K27me3), desmin, myogenin, CD99, epithelial membrane antigen (EMA) and transducin-like enhancer of split 1 (TLE1) on six primary intracranial sarcomas, DICER1-mutant, with appropriate controls. Targeted exome sequencing was performed on all cases. The sarcomas showed diffuse (n = 4), mosaic (n = 1) or minimal (≤5%, n = 1) loss of H3K27 trimethylation and nuclear TLE1 expression (n = 6). Four had immunohistochemical evidence of myogenic differentiation. SOX2, SOX10, S100 and EMA were negative; CD99 expression ranged from focal cytoplasmic (n = 4) to crisp diffuse membranous (n = 2). One tumour had focal cartilaginous differentiation. Similar immunohistochemical findings were observed in a pleuropulmonary blastoma (albeit with focal TLE1 expression), a DICER1-related pineoblastoma, and an embryonal tumour with a multilayered rosette-like DICER1-related cerebellar tumour. Targeted exome sequencing confirmed the presence of pathogenic biallelic DICER1 mutations in all tumours included in this study. CONCLUSION: We conclude that H3K27me3 and TLE1 immunostains, when utilised in combination, can be helpful diagnostic markers for primary intracranial sarcoma, DICER1-mutant.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias Encefálicas / Histonas / Transducina / Ribonuclease III / RNA Helicases DEAD-box Limite: Adolescent / Aged / Child / Female / Humans / Infant / Male Idioma: En Revista: Histopathology Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Neoplasias Encefálicas / Histonas / Transducina / Ribonuclease III / RNA Helicases DEAD-box Limite: Adolescent / Aged / Child / Female / Humans / Infant / Male Idioma: En Revista: Histopathology Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos